Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172515 | 1.00 | CYP3A4 (0.53) | CYP3A4CYP2D6BCHEWNT1GSK3B | |
| SCHEMBL490080 | 1.00 | CYP3A4 (0.53) | CYP3A4CYP2D6BCHEWNT1GSK3B | |
| Hydrochloric Acid SCHEMBL490045 | 0.98 | CYP3A4 (0.51) | CYP3A4CYP2D6BCHEWNT1GSK3B | |
| SCHEMBL12443460 | 0.94 | CYP3A4 (0.47) | CYP3A4CYP2D6BCHEWNT1GSK3B | |
| SCHEMBL9921656 | 0.94 | CYP3A4 (0.47) | CYP3A4CYP2D6BCHEWNT1GSK3B | |
| SCHEMBL26287093 | 0.94 | CYP3A4 (0.47) | CYP3A4CYP2D6BCHEWNT1GSK3B | |
| SCHEMBL18800228 | 0.92 | CYP3A4 (0.46) | CYP3A4CYP2D6BCHEPARP1KDM4E | |
| SCHEMBL31734262 | 0.92 | CYP3A4 (0.46) | CYP3A4CYP2D6BCHEPARP1KDM4E | |
| SCHEMBL15374826 | 0.87 | — | — | |
| SCHEMBL29865289 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449191-B1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | claimed |
| US-5438054-A | Antibacterial agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | claimed |
| WO-1991014687-A1 | 2-(SUBSTITUTED PYRROLIDINYLTHIO)CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-03 | — | — | WO | claimed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | claimed |
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2021257916-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257917-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3831823-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| EP-1611122-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-0449191-B1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5438054-A | Antibacterial agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| US-5374720-A | A thienamycins bactericides has nontoxic, side effect reduction against the kidney and central nervous system | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-12-20 | — | — | US | disclosed |
| WO-1991014687-A1 | 2-(SUBSTITUTED PYRROLIDINYLTHIO)CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-03 | — | — | WO | disclosed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP3A4 3093/4885CYP2D6 2791/4885BCHE 4796/4885 |
| US-20230323345-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | UPF1, HNRNPUL1, HNRNPUL2 | CYP3A4 4881/4885CYP2D6 4878/4885BCHE 4736/4885 |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | NR0B1, NR0B2, NR2C2 | CYP3A4 371/4885CYP2D6 188/4885BCHE 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.